Exvade Biosciencetm, a clinical-stage neuro-oncology company advancing a breakthrough platform for treating aggressive brain cancers, today highlighted ongoing enrollment in a Phase 1 clinical trial ...
VANCOUVER, BC, Jan. 6, 2026 /PRNewswire/ - GoldMining Inc. (the "Company" or "GoldMining") (TSX: GOLD) (NYSE American: GLDG) is pleased to report additional assay results from the 2025 RC ...
Introduction After the WHO prequalified the first vaccine against mpox, we aimed to identify the influence of vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback